

ASX Release

Appendix 4C – Q2 2026 Quarterly Cash Flow Report

29 July 2026 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) ("Oneview" or "the Company"), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 30 June 2026 (Q2 26) and provided an update on business activities.

Financial Highlights

Oneview's cash balance at 30 June 2026 was €7.2 million (A\$11.9m) compared to €10.3 million (A\$17.1m) at 31 March 2026.

In March 2026, the Company completed a two-tranche institutional placement raising A\$19 million (approximately €11.4 million) in gross proceeds, materially strengthening its balance sheet and providing funding to support execution of its growth strategy. Tranche 1 of the Placement, which raised A\$12 million (approximately €7.2 million), was settled on 24 March 2026. Tranche 2 of the Placement, which will raise a further A\$7 million (approximately €4.2 million) in gross proceeds, remains subject to shareholder approval. Settlement of Tranche 2 will occur following receipt of this approval, which the Company expects to seek at its annual general meeting anticipated to be held in September 2026. On a pro forma basis, assuming completion of Tranche 2, the Company's cash balance at 30 June 2026 would have been approximately €11.4 million (A\$18.9 million).

The Company recorded a net operating cash outflow of €2.9 million during the quarter, compared to an outflow of €3.8 million in the corresponding period of 2025. The lower cash outflow primarily reflects reduced spend driven by tighter cost control and efficiency initiatives across the business.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates are included in item 6.1 of the Appendix 4C. Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees and salaries totalling €235,851 (A\$387,598).

Operational Activities

Sales and Customer Updates

In May 2026, Oneview announced that it had launched a new revenue channel, Bedside Hub, designed to host Epic MyChart Bedside TV on healthcare-grade hardware with cloud-based device management, following its certification by Epic. Since achieving certification, the Company has experienced significant interest from health systems evaluating Epic TV deployments and has developed a growing pipeline of Bedside Hub-related opportunities. Based on the current outlook for these opportunities, the Company is targeting the addition of approximately three to four new Bedside Hub customers during the second half of 2026. The

Company has been invited to attend the Epic User Group Meeting (UGM) in Wisconsin, United States, on 17 August 2026 providing an opportunity for Oneview to showcase its solution and engage with healthcare organisations, partners and prospective customers.

Engagement between Oneview and one of the United States' ten largest health systems continues to advance following the inclusion of Oneview's products under an amendment to Baxter's National Care Communication Agreement with the health system's group purchasing organisation earlier this year. The Company expects to initiate projects with the health system during the second half of 2026. The opportunity represents a significant potential expansion pathway across a health system comprising more than 85 hospitals and 15,000 beds.

The Company also continued to advance its commercial pipeline and to progress expansion opportunities within its existing customer base during the quarter, as well as progressing deployments across its customer base.

A comprehensive update on the Company's operational and commercial progress will be provided as part of its half-year results presentation, which the Company announced earlier today will be released on 27 August 2026.

Product Updates

During the quarter, the Company continued development of its redesigned patient user interface, which is approaching completion. Development progressed across Service Requests, Patient Schedules and Patient Surveys, with enhancements focused on usability, accessibility and workflow management. As noted above, the Company launched Bedside Hub, its Epic MyChart Bedside TV solution, further expanding its patient engagement platform within the Epic ecosystem.

In parallel, planning progressed for the initial pilot deployments of Ovie, the Company's AI-powered digital Care Assistant, with pilot sites identified, project charters agreed and implementation planning underway. These pilots are expected to support the validation of workflows, user experience and operational impact ahead of broader commercialization. The Company also completed a re-architecture of its data analytics platform, enabling more frequent data updates and improved access to operational and engagement insights.

Outlook

CEO James Fitter commented, "The second quarter was another period of solid execution for Oneview. We continued to progress the business through a number of strategic, commercial and product initiatives while exercising disciplined cost management.

We were particularly pleased with the market response following the launch and certification of Bedside Hub, which has generated a growing pipeline of opportunities. We also continued to advance engagement with one of the United States' largest health systems following the inclusion of Oneview's products under an amendment to Baxter's National Care Communication Agreement with the health system's group purchasing organisation earlier this year. Alongside these commercial initiatives, we continued to progress the development of Ovie and other important product features, to support our future growth.

The progress achieved to date, combined with the strength of our opportunity pipeline and product roadmap, gives us confidence in delivering a strong second half of 2026. We look forward to providing shareholders with a more comprehensive update on our operational, commercial and financial performance when we release our half-year results on 27 August 2026."

This announcement has been approved for release by the board of Oneview Healthcare plc.

About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, Ireland, the Middle East and Asia to unify the care experience, in over 80 hospitals.

Enquiries:

James Fitter, CEO

Darragh Lyons, CFO

Website : www.oneviewhealthcare.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")

30th June 2026

Consolidated statement of cash flows		Current quarter €'000	Year to date (6 months) €'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	1,879	5,142
1.2	Payments for		
	(a) research and development	0	595
	(b) product manufacturing and operating costs	(1,056)	(1,638)
	(c) advertising and marketing	(85)	(280)
	(d) leased assets	-	-
	(e) staff costs	(2,877)	(5,726)
	(f) administration and corporate costs	(1,194)	(2,235)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	27	33
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes (paid)/refunded	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (working capital movements)	394	(72)
1.9	Net cash from / (used in) operating activities	(2,912)	(4,181)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(35)	(135)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(35)	(135)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	186	7,411
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(189)	(598)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(2)	6,813

Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	10,315	4,602
4.2	Net cash from / (used in) operating activities (item 1.11 above)	(2,912)	(4,181)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(35)	(135)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(2)	6,813
4.5	Effect of movement in exchange rates on cash held	(175)	91
4.6	Cash and cash equivalents at end of period	7,190	7,190

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	7,190	10,315
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	7,190	10,315

6.	Payments to related parties of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	236
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	€'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(2,912)
8.2 Cash and cash equivalents at quarter end (item 4.6)	7,190
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	7,190
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.5
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/a	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/a	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/a	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:28 July 2026.....

Authorised by: **BY THE BOARD**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.